Phase 2 Myeloma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

About the patient's diagnosis:

• People diagnosed with one of the following blood cancers (confirmed by tissue testing): Acute Myeloid Leukaemia (AML) that is in remission or not rapidly worsening; Myelodysplastic Syndrome (MDS); Chronic Myeloid Leukaemia (CML) in a stable or early advanced phase; a group of bone marrow disorders called Myeloproliferative Diseases (MPD) that have not reached a severe stage; an overlap condition called MDS/MPD; Acute Lymphoblastic Leukaemia (ALL) in remission; Multiple Myeloma; Chronic Lymphocytic Leukaemia (CLL); Non-Hodgkin's Lymphoma (aggressive types must be responding to chemotherapy); or Hodgkin's Disease that is responding to chemotherapy or checkpoint inhibitor treatment

About the patient's situation:

• People who would normally be considered for a standard bone marrow transplant from a donor, but for whom that approach is not possible due to being over 50 years old, having organ health concerns, or a decision made by the patient or their doctor
• People with a lower-risk blood cancer for whom a less intensive transplant preparation approach is considered more appropriate (such as CLL or Mantle Cell Lymphoma)

Other patient criteria:

• People aged 18 to 75 years old (children are not eligible for this trial)
• People who are able to use reliable contraception during and for 12 months after treatment, if they are able to have children
• People who have given their informed consent to participate (or whose legal guardian has done so where applicable)

About the stem cell donor:

• The donor can be male or female, of any age
• The donor must be either a brother or sister who is a full tissue-type (HLA) match, or an unrelated donor who matches on all 10 relevant tissue-type markers
• The donor must weigh more than 15 kg
• The donor must meet standard medical requirements for donating blood stem cells through a procedure called leukapheresis
• The donor must have given informed consent to donate (or their legal guardian has done so where applicable)

Who may not be able to join:

Patients:

• People who are HIV positive
• People who have had a non-blood cancer (other than common skin cancers) that was active within the 3 years before transplant
• People whose life expectancy is severely limited by a condition other than their blood cancer
• People whose cancer has spread to the central nervous system and has not responded to treatment delivered directly into the spinal fluid
• People with severe heart problems, including significant coronary artery disease, a heart pumping function below 40%, uncontrolled irregular heartbeat, or uncontrolled high blood pressure
• People with severe lung problems, including a lung carbon monoxide transfer capacity below 40%, a need for continuous supplementary oxygen, or a key breathing measurement (FEV1) below 40%
• People with severe liver conditions, including liver failure, cirrhosis with complications, alcoholic hepatitis, bleeding from oesophageal veins, liver-related brain problems, certain chronic viral liver infections with high bilirubin levels, or blocked bile ducts, among other serious liver conditions (confirm with trial site for full details)
• People with an infection that is not currently under control
• People whose general health and ability to perform daily activities falls below a set threshold on a standard medical scoring scale (Karnofsky score below 70%)
• People who are pregnant or breastfeeding
• People who are able to have children but are unwilling to use contraception during and for 12 months after treatment
• People for whom the conditioning medications used in this trial (melphalan or Thymoglobulin) cannot be safely used

Donors:

• Donors who are unable to undergo the stem cell collection procedure (leukapheresis) due to poor vein access or other reasons
• Donors who do not meet the inclusion criteria listed above

Important: Always verify eligibility with the trial site directly before applying.